<DOC>
	<DOCNO>NCT00492297</DOCNO>
	<brief_summary>The purpose study see whether new type anti-cancer drug , know BAY 43-9006 , give safely good effect combination dacarbazine ( DTIC ) . DTIC current standard chemotherapy drug give melanoma spread body . Although drug effective generally well tolerate , patient benefit , need test new drug drug combination treat melanoma .</brief_summary>
	<brief_title>A Phase II , Multi-Center , Open-Label , Uncontrolled Study Evaluate Efficacy Safety Sorafenib Given Daily Combination With Repeated 21-Day Cycles Dacarbazine ( DTIC ) Chemotherapy Subjects With Advanced Metastatic Melanoma</brief_title>
	<detailed_description>Issues `` Safety '' outcome address Adverse Event section .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Subjects advance , metastatic , histologically confirm melanoma , treatment dacarbazine consider medically acceptable Age &gt; = 18 year Subject measurable evaluable disease define least one metastatic lesion accurately serially measure Computed Tomography ( CT ) Magnetic Resonance Imaging ( MRI ) scan per Response Evaluation Criteria Solid Tumors ( RECIST ) criterion . Cutaneous lesion measure least 20mm long diameter consider measurable ( therefore target lesion ) via color photography include ruler Subject biopsiable disease baseline willing provide biopsy sample , biopsiable disease baseline Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Primary ocular mucosal melanoma ( cutaneous vulval melanoma permit ) Previous concurrent cancer distinct primary site histology cancer evaluate study EXCEPT cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor [ Ta , Tis &amp; T1 ] cancer curatively treat &gt; 3 year prior study entry ( Active coronary artery disease ischemia ( myocardial infarction 6 month prior study entry allow ) Uncontrolled hypertension ( &gt; grade 2 National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE ) version 3.0 ) Active , clinically serious infection ( &gt; grade 2 NCICTCAE version 3.0 ) Subjects seizure disorder require medication exclude History suspect Human Immunodeficiency Virus ( HIV ) infection , chronic hepatitis B C Symptomatic metastatic brain meningeal tumor unless subject &gt; 6 month definitive therapy , negative imaging study within 4 week prior study entry clinically stable respect tumor time study entry . Also subject must undergo acute steroid therapy taper ( chronic steroid therapy acceptable provide dose stable one month prior follow screen radiographic study ) Pregnant breastfeed subject</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>